SCHEMBL35210430

SCHEMBL35210430

C#CCOc1ccc(-c2noc(-c3ccc(O)cc3)n2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 5/20 0.49
S1PR3 Q99500 1/20 0.49
MAOA P21397 4/20 0.49
MAOB P27338 4/20 0.49
NPC1 O15118 7/20 0.46
RAB9A P51151 6/20 0.46
SMN1; SMN2 Q16637 6/20 0.46
MAPT P10636 3/20 0.46
NPSR1 Q6W5P4 2/20 0.46
ACHE P22303 1/20 0.46
NR1H4 Q96RI1 1/20 0.46
AOC3 Q16853 2/20 0.46
NFKB1 P19838 2/20 0.44
NFKB2 Q00653 2/20 0.44
RELA Q04206 2/20 0.44
TP53 P04637 2/20 0.44
PKM P14618 1/20 0.44
HSD17B10 Q99714 1/20 0.44
S1PR5 Q9H228 1/20 0.43
GAA P10253 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL35210441 0.87 S1PR1 (0.53) S1PR1S1PR3NPC1RAB9ASMN1; SMN2
SCHEMBL35210453 0.82 NPC1 (0.64) S1PR1S1PR3NPC1RAB9ASMN1; SMN2
SCHEMBL21153753 0.80 S1PR1 (0.76) S1PR1S1PR3NPC1RAB9ASMN1; SMN2
SCHEMBL35210439 0.80 S1PR1 (0.67) S1PR1S1PR3NPC1RAB9ASMN1; SMN2
SCHEMBL14901605 0.79 GSTP1 (0.58) MAOAMAOBACHEGAAMGAM
SCHEMBL19968904 0.78 STAT3 (0.54) S1PR1S1PR3NPC1RAB9ASMN1; SMN2
SCHEMBL21153222 0.78 S1PR1 (0.55) S1PR1S1PR3NPC1RAB9ASMN1; SMN2
SCHEMBL975819 0.77 CA12 (0.53) MAOAMAOBACHEGAAMGAM
SCHEMBL3057134 0.77 RAB9A (0.74) S1PR1NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL5836424 0.74 NR1H4 (0.66) S1PR1MAOAMAOBNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125371-A1 METHOD FOR INHIBITING CLOSTRIDIOIDES DIFFICILE SPORE GERMINATION UNIVERSITY OF NOTRE DAME DU LAC (US) 2026-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125371-A1 METHOD FOR INHIBITING CLOSTRIDIOIDES DIFFICILE SPORE GERMINATION CYP8B1, SPOUT1, O60361 S1PR1 3111/4885S1PR3 2606/4885MAOA 2520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.